Clinical trials: Overweight or Obese Adults
Obesity, Obese
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
- Conditions
- Obesity, Obese, Overweight or Obesity
- Trial name
- NCT05616013
- Testing
- Bimagrumab, Semaglutide
- Where
- 26 sites in United States, Australia and 1 more
- Volunteers
- 507 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese.
- Trial name
- NCT05677867
- Testing
- Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066…
- Trial name
- NCT03100058
- Testing
- LIK066
- Where
- 83 sites in United States, Austria and 5 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Overweight or Obesity
- Trial name
- ATTAIN-1 (NCT05869903)
- Testing
- Orforglipron
- Where
- 138 sites in United States, Brazil and 8 more
- Volunteers
- 3,127 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Study of a Healthy Lifestyle Intervention for Deaf Adults Who Are Overweight or Obese
The purpose of the Deaf Weight Wise study is to test a 16 week, evidence-based, comprehensive program to change obesity-related health behaviors in Deaf people who use American Sign Language (ASL) as their primary language.
- Trial name
- DWW (NCT01452269)
- Testing
- Deaf Weight Wise program
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Healthy
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults
This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or…
- Trial name
- NCT05745701
- Testing
- PF-07081532, Cyclosporine, Itraconazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight or Obesity
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
- Trial name
- FALCON (NCT06854952)
- Testing
- TERN-601
- Where
- 17 sites in United States
- Volunteers
- 167 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants.
- Trial name
- NCT05788328
- Testing
- Dabigatran etexilate (DE), Rosuvastatin, PF-07081532
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2…
- Trial name
- SURMOUNT-5 (NCT05822830)
- Testing
- Tirzepatide, Semaglutide
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 751 people
- Sponsor
- Eli Lilly and Company
Obesity
Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans
The purpose of this study is to retrospectively and systematically review records of overweight and obese Medifast Weight Control Center (MWCC) members who have been assigned to the 5 \& 2 \& 2 Plan or the 4 \& 2 \& 1 Plan for…
- Trial name
- NCT02150837
- Testing
- 5 & 2 & 2 Plan, 4 & 2 & 1 Plan
- Where
- United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Medifast, Inc.
Obesity, Overweight or Obesity
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks.
- Trial name
- VESPER-1 (NCT06712836)
- Testing
- MET097
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Pfizer
Cardiovascular Diseases, Diabetes Mellitus
Evaluation of a Letter Intervention Promoting a Plant-based Diet
The researchers' mission is to promote healthier eating behavior and to reduce costs associated with healthcare. The purpose of this study is to evaluate the effects of mailing randomly selected participants a letter promoting a…
- Conditions
- Cardiovascular Diseases, Diabetes Mellitus, Obesity
- Trial name
- NCT03880838
- Testing
- Personal testimonial, Forks Over Knives Documentary, Commitment nudge
- Where
- United States
- Volunteers
- 11,234 people
- Sponsor
- Geisinger Clinic
Overweight and Obesity
Study of Produce Prescription Programs in Adults With Overweight or Obesity Experiencing Nutrition Insecurity
The goal of this study is to understand the best practices for implementing produce prescriptions among adults with overweight or obesity experiencing nutrition insecurity.
- Trial name
- NCT06751563
- Testing
- Behavioral Text Messages and Produce Box Delivery, Behavioral Text Message Program and Produce Voucher
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Johns Hopkins University
Obesity, Overweight
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- ATTAIN-2 (NCT05872620)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,613 people
- Sponsor
- Eli Lilly and Company
Obesity
Effect of a Unique Web-based Behaviour Change Program on Weight Loss and Cardiovascular Risk Factors
Web- or internet-based programs have the potential to induce and, possibly, help to sustain, significant lifestyle modification.
- Trial name
- NCT01472276
- Testing
- Web-based program
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Overweight, Obesity
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily.
- Trial name
- OASIS 4 (NCT05564117)
- Testing
- Semaglutide
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 307 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight and Obesity
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with Mazdutide compared with placebo and in adult participants with obesity or…
- Trial name
- NCT06124807
- Testing
- Mazdutide
- Where
- 29 sites in United States
- Volunteers
- 179 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Deaf Weight Wise 2.0: A Healthy Lifestyle Intervention With Deaf Adults Who Are Overweight or Obese
The purpose of the Deaf Weight Wise 2.0 (DWW 2.0) study is to test an evidence-based, comprehensive program to modify obesity-related health behaviors with Deaf people ages 21 to 70 who use American Sign Language (ASL) as their…
- Trial name
- DWW2 (NCT03060525)
- Testing
- Deaf Weight Wise 2.0
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Rochester